Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 35

1.

A systematic review of biomarkers for disease progression in Alzheimer's disease.

McGhee DJ, Ritchie CW, Thompson PA, Wright DE, Zajicek JP, Counsell CE.

PLoS One. 2014 Feb 18;9(2):e88854. doi: 10.1371/journal.pone.0088854. eCollection 2014. Review. Erratum in: PLoS One. 2014;9(5):e97960.

2.

A systematic review of biomarkers for disease progression in Parkinson's disease.

McGhee DJ, Royle PL, Thompson PA, Wright DE, Zajicek JP, Counsell CE.

BMC Neurol. 2013 Apr 12;13:35. doi: 10.1186/1471-2377-13-35. Review.

3.

Can the ABILHAND handle manual ability in MS?

Barrett LE, Cano SJ, Zajicek JP, Hobart JC.

Mult Scler. 2013 May;19(6):806-15. doi: 10.1177/1352458512462919. Epub 2012 Oct 24.

PMID:
23095289
4.

Machine learning-based method for personalized and cost-effective detection of Alzheimer's disease.

Escudero J, Ifeachor E, Zajicek JP, Green C, Shearer J, Pearson S; Alzheimer's Disease Neuroimaging Initiative.

IEEE Trans Biomed Eng. 2013 Jan;60(1):164-8. doi: 10.1109/TBME.2012.2212278. Epub 2012 Aug 8.

PMID:
22893371
5.

Bioprofile analysis: a new approach for the analysis of biomedical data in Alzheimer's disease.

Escudero J, Ifeachor E, Zajicek JP; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2012;32(4):997-1010. doi: 10.3233/JAD-2012-121024.

PMID:
22886027
6.

Multiple sclerosis and extract of cannabis: results of the MUSEC trial.

Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG; MUSEC Research Group.

J Neurol Neurosurg Psychiatry. 2012 Nov;83(11):1125-32. doi: 10.1136/jnnp-2012-302468. Epub 2012 Jul 12.

PMID:
22791906
7.

Machine Learning classification of MRI features of Alzheimer's disease and mild cognitive impairment subjects to reduce the sample size in clinical trials.

Escudero J, Zajicek JP, Ifeachor E; Alzheimer’s Disease Neuroimaging Initiative.

Conf Proc IEEE Eng Med Biol Soc. 2011;2011:7957-60. doi: 10.1109/IEMBS.2011.6091962.

PMID:
22256186
8.

Early detection and characterization of Alzheimer's disease in clinical scenarios using Bioprofile concepts and K-means.

Escudero J, Zajicek JP, Ifeachor E.

Conf Proc IEEE Eng Med Biol Soc. 2011;2011:6470-3. doi: 10.1109/IEMBS.2011.6091597.

PMID:
22255820
9.

Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease.

Carroll CB, Zeissler ML, Hanemann CO, Zajicek JP.

Neuropathol Appl Neurobiol. 2012 Oct;38(6):535-47. doi: 10.1111/j.1365-2990.2011.01248.x.

PMID:
22236282
10.

Health state values for use in the economic evaluation of treatments for Alzheimer's disease.

Shearer J, Green C, Ritchie CW, Zajicek JP.

Drugs Aging. 2012 Jan 1;29(1):31-43. doi: 10.2165/11597380-000000000-00000. Review.

PMID:
22191721
11.

The use of multiple sclerosis condition-specific measures to inform health policy decision-making: mapping from the MSWS-12 to the EQ-5D.

Hawton A, Green C, Telford CJ, Wright DE, Zajicek JP.

Mult Scler. 2012 Jun;18(6):853-61. doi: 10.1177/1352458511429319. Epub 2011 Nov 22.

PMID:
22108867
12.

Model-based economic evaluation in Alzheimer's disease: a review of the methods available to model Alzheimer's disease progression.

Green C, Shearer J, Ritchie CW, Zajicek JP.

Value Health. 2011 Jul-Aug;14(5):621-30. doi: 10.1016/j.jval.2010.12.008. Review.

PMID:
21839398
13.

The impact of motor and non motor symptoms on health state values in newly diagnosed idiopathic Parkinson's disease.

Shearer J, Green C, Counsell CE, Zajicek JP.

J Neurol. 2012 Mar;259(3):462-8. doi: 10.1007/s00415-011-6202-y. Epub 2011 Aug 5.

PMID:
21818689
14.

The use of decision-analytic models in Parkinson's disease: a systematic review and critical appraisal.

Shearer J, Green C, Counsell CE, Zajicek JP.

Appl Health Econ Health Policy. 2011 Jul 1;9(4):243-58. doi: 10.2165/11590160-000000000-00000. Review.

PMID:
21682352
15.

Changes in iron-regulatory gene expression occur in human cell culture models of Parkinson's disease.

Carroll CB, Zeissler ML, Chadborn N, Gibson K, Williams G, Zajicek JP, Morrison KE, Hanemann CO.

Neurochem Int. 2011 Aug;59(1):73-80. doi: 10.1016/j.neuint.2011.05.006. Epub 2011 Jun 6.

PMID:
21672570
16.

Designing clinical trials in older people.

Carroll CB, Zajicek JP.

Maturitas. 2011 Apr;68(4):337-41. doi: 10.1016/j.maturitas.2011.02.002. Epub 2011 Mar 3. Review.

PMID:
21376485
17.

Role of cannabinoids in multiple sclerosis.

Zajicek JP, Apostu VI.

CNS Drugs. 2011 Mar;25(3):187-201. doi: 10.2165/11539000-000000000-00000. Review.

PMID:
21323391
18.

Beyond the reach of traditional analyses: using Rasch to evaluate the DASH in people with multiple sclerosis.

Cano SJ, Barrett LE, Zajicek JP, Hobart JC.

Mult Scler. 2011 Feb;17(2):214-22. doi: 10.1177/1352458510385269. Epub 2010 Oct 14.

PMID:
20947530
19.
20.

Melanoma following treatment with alemtuzumab for multiple sclerosis.

Pace AA, Zajicek JP.

Eur J Neurol. 2009 Apr;16(4):e70-1. doi: 10.1111/j.1468-1331.2009.02552.x. No abstract available.

PMID:
19222552
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk